Has USANA Health Sciences (USNA) Outpaced Other Medical Stocks This Year?
Investors focused on the Medical space have likely heard of USANA Health Sciences (USNA), but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
USANA Health Sciences is a member of the Medical sector. This group includes 903 individual stocks and currently holds a Zacks Sector Rank of #8. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. USNA is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for USNA's full-year earnings has moved 8.63% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, USNA has gained about 3.58% so far this year. Meanwhile, stocks in the Medical group have gained about 1.97% on average. This shows that USANA Health Sciences is outperforming its peers so far this year.
Breaking things down more, USNA is a member of the Medical - Drugs industry, which includes 172 individual companies and currently sits at #101 in the Zacks Industry Rank. Stocks in this group have lost about 5.68% so far this year, so USNA is performing better this group in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to USNA as it looks to continue its solid performance.
Click to get this free report
USANA Health Sciences, Inc. (USNA): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.